Multiple agonist induction of aggregation: an approach to examine anti-aggregating effects in vitro.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 21043669)

Published in Platelets on January 01, 1996

Authors

S R Willoughby1, L P Chirkova, J D Horowitz, Y Y Chirkov

Author Affiliations

1: Cardiology Unit, North Western Adelaide Health Service, University of Adelaide, Adelaide, SA, Australia.

Articles by these authors

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06

Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet (1999) 2.88

Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med (1998) 2.65

Effects of home-based intervention on unplanned readmissions and out-of-hospital deaths. J Am Geriatr Soc (1998) 2.49

Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49

Heart failure in older people: the epidemic we had to have. Med J Aust (2001) 2.03

Is informed consent to clinical trials an "upside selective" process in acute coronary syndromes? Am Heart J (2000) 1.74

N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation (1995) 1.58

Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J (2000) 1.55

Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation (2000) 1.53

Nitrate resistance in platelets from patients with stable angina pectoris. Circulation (1999) 1.49

Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J (2001) 1.46

Utility of a weight-based heparin nomogram for patients with acute coronary syndromes. Intern Med J (2003) 1.46

Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J (2002) 1.44

Acute myocardial uptake of digoxin in humans: correlation with hemodynamic and electrocardiographic effects. J Am Coll Cardiol (1990) 1.41

Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med (1999) 1.33

Calcium antagonists: a new class of drugs. Pharmacol Ther (1983) 1.28

Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost (2010) 1.25

Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations. Lancet (1980) 1.24

Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol (1996) 1.22

Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics. Int J Cardiol (1986) 1.10

Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation (1983) 1.07

Peripherally inserted central catheters revisited. Am J Surg (1998) 1.01

Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease. Circulation (1983) 1.01

Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade. J Pharmacol Exp Ther (1989) 0.99

S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators. Br J Pharmacol (1989) 0.98

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med (2001) 0.94

Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther Drug Monit (1996) 0.92

Amelioration of renal ischaemia-reperfusion injury by liposomal delivery of curcumin to renal tubular epithelial and antigen-presenting cells. Br J Pharmacol (2012) 0.91

Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteine. J Cardiovasc Pharmacol (1985) 0.90

Drugs and impaired male sexual function. Drugs (1979) 0.90

Aortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk. Heart (2005) 0.89

High-performance liquid chromatographic assay of perhexiline maleate in plasma. J Pharm Sci (1981) 0.89

Neovascular complications associated with rubeosis iridis and peripheral retinal detachment after retinal detachment surgery. Am J Ophthalmol (1998) 0.89

Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol (2000) 0.88

Effects of captopril (SQ 14,225) in a patient with primary pulmonary hypertension. Postgrad Med J (1981) 0.87

Verapamil hepatotoxicity: a hypersensitivity reaction. Am Heart J (1986) 0.87

Determinants of in vitro nitroglycerin tolerance induction and reversal: influence of dose regimen, nitrate-free period, and sulfhydryl supplementation. J Cardiovasc Pharmacol (1989) 0.86

Home-based intervention: the next step in treatment of chronic heart failure? Eur Heart J (2000) 0.86

Cardiovascular responses to partial and total immersion in man. J Physiol (1969) 0.86

Recent developments in nitrate therapy of ischaemic heart disease. Med J Aust (1987) 0.84

Short-term myocardial uptake of lidocaine and mexiletine in patients with ischemic heart disease. Circulation (1986) 0.83

Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol (1997) 0.83

Prevention of aortic valve stenosis: a realistic therapeutic target? Pharmacol Ther (2012) 0.83

Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Card Fail (1998) 0.82

Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects. Am J Cardiol (1992) 0.82

Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide (2011) 0.82

D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. J Thromb Haemost (2014) 0.82

Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol (2001) 0.82

Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells. Br J Pharmacol (1985) 0.81

Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust N Z J Med (1997) 0.81

Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. Eur J Heart Fail (1999) 0.81

Surgery for carotid artery stenosis following neck irradiation. Ann Vasc Surg (2001) 0.81

Is perhexiline essential for the optimal management of angina pectoris? Aust N Z J Med (1995) 0.81

Indinavir nephropathy. N Engl J Med (1997) 0.81

Tolerance induction by transdermal glyceryl trinitrate in rats. Eur J Pharmacol (1999) 0.80

The effects of perhexiline on the rat coronary vasculature. Eur J Pharmacol (1999) 0.80

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. Eur J Heart Fail (2000) 0.80

Attenuation of coronary vascular resistance by selective alpha 1-adrenergic blockade in patients with coronary artery disease. J Am Coll Cardiol (1985) 0.80

Myocardial uptake of drugs and clinical effects. Clin Pharmacokinet (1987) 0.80

Usefulness of early exercise testing after non-Q-wave myocardial infarction in predicting prognosis. Am J Cardiol (1986) 0.80

High-performance liquid chromatographic determination of sotalol in plasma. I. Application to the disposition of sotalol enantiomers in humans. J Chromatogr (1992) 0.80

Prediction of outcome after revascularization in patients with poor left ventricular function. Ann Thorac Surg (1996) 0.79

Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.79

Antiplatelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris. J Cardiovasc Pharmacol (1993) 0.79

Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure. Eur J Heart Fail (2004) 0.79

The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide (2011) 0.79

Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure. Eur J Heart Fail (2001) 0.79

Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail (1998) 0.79

Use of dopamine and prazosin combined in the treatment of cardiogenic shock. Med J Aust (1980) 0.79

Hypertension and postural hypotension induced by phenylpropanolamine (Trimolets). Med J Aust (1979) 0.78

Extraction of plasma prorenin by human heart. Lancet (1986) 0.78

Lack of interaction between digoxin and quinidine in cultured heart cells. J Pharmacol Exp Ther (1982) 0.78

Can a nurse trained in coronary care expedite emergency department management of patients with acute coronary syndromes? Heart Lung (2001) 0.78

Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity. J Cardiovasc Pharmacol (1990) 0.78

Measurement of penicillamine and N-acetylcysteine in human blood by high-performance liquid chromatography and electrochemical detection. J Chromatogr (1986) 0.78

Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes. Intern Med J (2004) 0.78

Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol (2001) 0.78

Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. J Cardiovasc Pharmacol (1981) 0.77

N-Acetylcysteine potentiates nitroglycerin-induced reversal of platelet aggregation. J Cardiovasc Pharmacol (1996) 0.77

Myocardial effect compartment modeling of metoprolol and sotalol: importance of myocardial subsite drug concentration. J Pharm Sci (1998) 0.77

The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness. Nitric Oxide (2013) 0.77

Perhexiline maleate in the treatment of severe angina pectoris. Med J Aust (1979) 0.77

S-nitrosothiol modulation of tolerance to glyceryl trinitrate in bovine isolated coronary artery. Eur J Pharmacol (1994) 0.77

Effects of glyceryl trinitrate tolerance on vascular responsiveness to constrictor agents in bovine isolated coronary artery. Clin Exp Pharmacol Physiol (1995) 0.77

Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist. Cardiovasc Res (1998) 0.77

Effects of guanylyl cyclase and protein kinase G inhibitors on vasodilatation in non-tolerant and tolerant bovine coronary arteries. Eur J Pharmacol (1999) 0.76

Magnetic resonance angiography in the preoperative evaluation of abdominal aortic aneurysms. Am J Surg (1993) 0.76

Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol (1998) 0.76

Lack of inhibition of glyceryl trinitrate by diphenyleneiodonium in bovine coronary artery. Eur J Pharmacol (1996) 0.76

Sotalol-induced torsade de pointes: management with magnesium infusion. Postgrad Med J (1992) 0.76